0
Pipeline Programs↗
0
Active Trials↗
1
Companies Involved↗
PCOS is an early-stage landscape with 0 programs across 1 company. The most active players are Margan Biotech.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
20
clinical trials
Completed14 · 70%
Unknown status3 · 15%
Withdrawn2 · 10%
Terminated1 · 5%
Clinical Trials
Trial Activity
20 trials
Letrozole Dose Increments in PCOS Patients Resistant to Letrozole
Completed·—·Phase 3·NCT06403488·102 enrolled
Effect of Drospirenone-Ethinyl Estradiol (20microgram vs 30 Microgram) on Free Androgen Index in PCOS
Completed·—·N/A·NCT07318337·60 enrolled
NAC in CC Resistant PCOS After LOD
Completed·—·Phase 2/3·NCT02775734·144 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)